Compare Main Street Capital Corporation (MAIN) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Repligen Corporation Common Stock — how do they compare? Main Street Capital Corporation trades at $53.36 (market cap $5.03B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 2.2× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 5.91% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 89 Days and Repligen Corporation Common Stock for 0 Days on average.
| MAIN | RGEN | |
|---|---|---|
Market Cap | $5.03B | $11.14B |
Volume | 386,945 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $64.60 | $194.57 |
52-Week Low | $49.63 | $102.87 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $7.48B | $11.02B |
Dividend Yield | 5.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAIN trades at $53.50, down 0.3% on the day, with a bearish technical signal and key support at $53. The stock shows strong profitability with an 80.77% net margin and a P/E of 10.8, but revenue declined slightly in 2025 to $592M. Recent quarterly earnings have been mixed, beating in Q2 2026 but missing in Q1. The company maintains a consistent dividend, with recent payments of $0.27-$0.30 per share.
The outlook is cautious; while MAIN's high margins and dividend yield near 7.9% appeal to income investors, bearish technicals, softening revenue, and a high proportion of analyst 'Hold' ratings suggest limited near-term upside. Risks include earnings volatility and sensitivity to interest rates, but the stock trades below the consensus price target of $58, offering potential appreciation if fundamentals stabilize.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
